Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban plus aspirin versus aspirin alone after lower extremity revascularization in symptomatic peripheral artery disease
NL-OMON42582Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of rivaroxaban and aspirin, sponsored by Bayer. Started Apr 2016; status: active, not recruiting.
02
Drugs
rivaroxabanaspirin
Beyond the preview
Go deeper on NL-OMON42582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42582.